Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Reserpine enhances dendritic cell cross-presentation and strengthens CD8+ T cell-mediated antitumor immunity. Local targets link to admitted publications; unresolved targets remain external evidence.
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
10.1056/nejmoa1910836 · 2019 · External reference
Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%
10.1200/jco.21.00174 · 2021 · External reference
Primary, adaptive, and acquired resistance to cancer immunotherapy
10.1016/j.cell.2017.01.017 · 2017 · External reference
Top 10 challenges in cancer immunotherapy
10.1016/j.immuni.2019.12.011 · 2020 · External reference
Dendritic cells in cancer immunology and immunotherapy
10.1038/s41577-019-0210-z · 2020 · External reference
The cancer-immunity cycle: indication, genotype, and immunotype
10.1016/j.immuni.2023.09.011 · 2023 · External reference
The biology and underlying mechanisms of cross-presentation of exogenous antigens on MHC-I molecules
10.1146/annurev-immunol-041015-055254 · 2017 · External reference
Antigen cross-presentation by dendritic cells: a critical axis in cancer immunotherapy
10.1016/j.smim.2023.101848 · 2024 · External reference
Cutting edge: phagosome-associated autophagosomes containing antigens and proteasomes drive TAP-independent cross-presentation
2024 · External reference
The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen
10.1111/j.1365-2567.2012.03558.x · 2012 · External reference
The role of pattern-recognition receptors in innate immunity: update on toll-like receptors
10.1038/ni.1863 · 2010 · External reference
Toll-like receptors: the swiss army knife of immunity and vaccine development
10.1038/cti.2016.22 · 2016 · External reference
Key roles of adjuvants in modern vaccines
10.1038/nm.3409 · 2013 · External reference
Natural products in drug discovery: advances and opportunities
10.1038/s41573-020-00114-z · 2021 · External reference
The biological fate of reserpine
10.1016/s0031-6997(25)06712-2 · 1976 · External reference
Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects
10.1017/s1092852917000621 · 2018 · External reference
Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines
10.1038/s41422-023-00906-z · 2024 · External reference
Reserpine, a novel N6-methyladenosine regulator, reverses Lenvatinib resistance in hepatocellular carcinoma
10.1016/j.phymed.2024.156002 · 2024 · External reference
The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer
10.1038/s41590-024-02068-5 · 2025 · External reference
Regulation of intercellular biomolecule transfer-driven tumor angiogenesis and responses to anticancer therapies
10.1172/jci144225 · 2021 · External reference
Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8(+) Tcells in lymph nodes
10.1038/s41590-026-02419-4 · 2026 · External reference
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
10.1038/s41590-022-01141-1 · 2022 · External reference
Clonal replacement of tumor-specific T cells following PD-1 blockade
10.1038/s41591-019-0522-3 · 2019 · External reference
PA28 and the proteasome immunosubunits play a central and independent role in the production of MHC class I-binding peptides in vivo
10.1002/eji.201041040 · 2011 · External reference
Proteasome inhibitors in cancer therapy
10.1038/nrclinonc.2016.206 · 2017 · External reference
Cellular responses to proteasome inhibition: molecular mechanisms and beyond
10.3390/ijms20143379 · 2019 · External reference
Understanding the tumor immune microenvironment (TIME) for effective therapy
10.1038/s41591-018-0014-x · 2018 · External reference
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
10.1038/s41573-018-0007-y · 2019 · External reference
β2-Adrenoreceptor agonist inhibits antigen cross-presentation by dendritic cells
2013 · External reference
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
10.1038/s41568-021-00339-z · 2021 · External reference
Cancer immune escape: the role of antigen presentation machinery
10.1007/s00432-023-04737-8 · 2023 · External reference
Infiltration characteristics and regulatory mechanisms of CD8(+) T lymphocytes in solid tumors: spatial distribution, biological functions, and interactions with the immune microenvironment
10.3389/fimmu.2025.1661545 · 2025 · External reference
Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease
10.1124/pr.114.010397 · 2015 · External reference
